文献速递血管炎

抗中性粒细胞胞质抗体相关性血管炎患者报告结局(AAV-PRO)问卷的验证

Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire.
PubMed 文献 · Ann Rheum Dis · 2018-04-25

研究基于英国、美国、加拿大50次定性访谈形成的35条目候选问卷,通过纵向调查确定最终量表结构并验证AAV-PRO。纳入626例AAV患者,探索性因子分析和Rasch分析支持29条目六维度量表;活动性疾病患者各维度得分高于缓解期(p<0.001),与EQ-5D-5L相关性r=-0.55至0.78(均p<0.0001),重测信度ICC 0.89-0.96。

要点

  • AAV-PRO为29条目六维度疾病特异性患者报告结局量表。
  • 活动性疾病患者各维度得分高于缓解期,p<0.001。
  • 重测信度ICC 0.89-0.96,与EQ-5D-5L相关性r=-0.55至0.78。

核心结论

  • AAV-PRO这一新的AAV疾病特异性患者报告结局量表具有良好的表面效度和结构效度,可靠、可行,并能区分不同疾病状态。

研究设计与样本

  • 基于英国、美国、加拿大50次定性访谈形成的35条目候选问卷,开展纵向调查以确定最终量表结构并验证AAV-PRO。
  • 通过Vasculitis UK和Vasculitis Patient-Powered Research Network招募参与者,基线及3个月时完成35条目候选问卷。
  • 英国参与者完成EuroQol-5D-5L(EQ-5D-5L),美国参与者在基线后3-5天进行重测练习。
  • 采用探索性因子分析和Rasch分析确定量表结构,评估聚合效度、已知组效度、重测信度和纵向结构效度。
  • 共纳入626例AAV患者,>25%报告「活动性疾病」。

主要发现

  • 探索性因子分析和Rasch分析支持29条目量表,包含六个维度:「器官特异性症状」「全身症状」「治疗副作用」「社会与情感影响」「对未来的担忧」和「躯体功能」。
  • 活动性疾病患者各维度平均得分高于缓解期患者(p<0.001)。
  • 各维度得分与EQ-5D-5L的相关性范围为r=-0.55至0.78,均p<0.0001。
  • 在报告「无变化」的参与者(n=97)中,各维度组内相关系数较高(范围0.89-0.96)。

关键数值与推荐

  • 最终AAV-PRO为29条目六维度量表:器官特异性症状、全身症状、治疗副作用、社会与情感影响、对未来的担忧、躯体功能。
  • 活动性疾病与缓解期各维度平均得分比较p<0.001。
  • 维度得分与EQ-5D-5L相关性r=-0.55至0.78,均p<0.0001。
  • 报告「无变化」参与者(n=97)各维度ICC范围0.89-0.96。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To finalise and validate a disease-specific patient-reported outcome (PRO) measure: the ANCA-associated vasculitis patient-reported outcome (AAV-PRO) questionnaire. Using a 35-item candidate questionnaire developed following 50 qualitative interviews in the UK, USA and Canada, a longitudinal survey was conducted to determine the final scale structure and validate the AAV-PRO. METHODS: Participants were recruited via Vasculitis UK and the Vasculitis Patient-Powered Research Network. The 35-item candidate questionnaire was completed at baseline and 3 months; UK participants completed the EuroQol-5D-5L (EQ-5D-5L), while US participants completed a test-retest exercise, 3-5 days after baseline. Scale structure was defined using exploratory factor analysis (EFA) and Rasch analysis. Convergent and known groups validity, test-retest reliability and longitudinal construct validity were assessed. RESULTS: There were 626 participants with AAV; >25% reporting 'active disease'. EFA and Rasch analysis supported a 29-item profile measure comprising six domains: 'organ-specific symptoms', 'systemic symptoms', 'treatment side effects', 'social and emotional impact', 'concerns about the future' and 'physical function'. Mean domain scores were higher for participants with 'active disease' versus 'remission' (p<0.001). Construct validity was demonstrated by correlations between domain scores and the EQ-5D-5L (range r=-0.55 to 0.78), all p<0.0001. In participants reporting 'no change' (n=97) during the test-retest, intraclass correlation coefficient values were high (range 0.89-0.96) for each domain. CONCLUSIONS: The AAV-PRO, a new disease-specific PRO measure for AAV, has good face and construct validity, is reliable, feasible and discriminates among disease states.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Robson JC, Dawson J, Doll H, et al. Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire. Ann Rheum Dis. 2018. PMID: 29695498. doi:10.1136/annrheumdis-2017-212713

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。